A personal cleansing composition includes a surfactant system, wherein the surfactant system includes from 0.1% to 5% of a fatty acyl isethionate surfactant by weight of the composition; from 0.5% to 40% of a co-surfactant by weight of the composition; from 0.05% to 5% of a natural polysaccharide or a chemically modified natural polysaccharide by weight of the composition; wherein the personal cleansing composition includes a first and second phase, wherein the first phase is an isotropic and micellar surfactant phase; wherein the second phase is a polymer liquid crystalline phase; wherein the composition is free of alkyl sulfate and alkyl ether sulfate type of surfactants; wherein the composition exhibits a yield stress value τ.sub.y from 0.005 Pa to 3 Pa; and wherein the composition exhibits a flow viscosity from 3 Pa.Math.s to 100 Pa.Math.s at 25° C. at a shear rate of 1.5 s.sup.−1.

Described is a high-concentrate flowable liquid anionic surfactant composition containing an alkyl ether sulfate and a viscosity modifier(s). The composition avoids the highly viscous gel phase that occurs when concentrated anionic surfactants are diluted with an aqueous solvent. Also described, is a personal care composition of the high-concentrate flowable liquid anionic surfactant composition.

The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents including phage and phagemids delivering peptides, therapeutic antibodies, DNA and RNA-based therapeutics that results in treating inflammation of a variety of disorders including psoriasis, atopic dermatitis and inflammatory bowel disease. The invention also provides bacteria that inhibit the growth of intestinal parasites such as worms, and deliver siRNA or miRNA that have specific anti-parasitic effects that results in the reduction or elimination of the parasite.

A packaged aerosol foaming skin cleanser can include a multiphase skin cleansing composition, a low pressure foaming agent, and a package.

This invention provides particles encapsulating colorant that do not produce functional effects or remove functional effects until they are triggered by contacting with at least one exogenous source. The particles in this invention minimize toxic effects the body of the colorant and the material that interacts with an exogenous source as well as minimize body chemicals from degrading both the colorant and the material that interacts with an exogenous source inside the particle.

A method is described for producing a dosage form. Also described, are granules and tablets obtained by the method. The use of a surface-reacted calcium carbonate in such a method, a dosage form comprising the granules, the use of the granules, or the tablets and/or capsules, or the dosage form in a pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product as well as pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product including such granules, or the tablets and/or capsules, or the dosage form are also described.

A method is described for producing a dosage form. Also described, are granules and tablets obtained by the method. The use of a surface-reacted calcium carbonate in such a method, a dosage form comprising the granules, the use of the granules, or the tablets and/or capsules, or the dosage form in a pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product as well as pharmaceutical product, a nutraceutical product, an agricultural product, a cosmetic product, a home product, a food product, a packaging product and a personal care product including such granules, or the tablets and/or capsules, or the dosage form are also described.

Compositions and methods of manufacture for an extended time-release fragrance comprising volatile organic compounds. A composition of the disclosure includes an effective amount of a volatile organic compound for providing a fragrance that can be sensed by a user and fractionated coconut oil comprising caprylic acid and capric acid.

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.